Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
Authors:
Open Access
- 25 March 2025
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-13
Abstract
The anti-HER2 monoclonal antibody trastuzumab and new derivative formulations are the standard treatment for HER2-positive breast cancer. However, after 1 to 5 years of treatment, some patients acquire resistance to therapy, leading to relapse. The microRNA-449 family members were downregulated in HER2-positive breast cancer cell lines and low levels were associated with patients’ worse prognosis. Moreover, trastuzumab-resistant HER2-positive breast cancer cell lines showed lower microRNAs-449 and higher Fatty Acid Synthase (FASN) expression, compared to sensitive cell lines. The direct regulation of FASN by microRNA-449a and microRNA-449b-5p was demonstrated. Moreover, microRNAs-449 overexpression and FASN inhibition decreased cell proliferation and sensitized cells to trastuzumab treatment by inhibiting the PI3K/AKT signaling pathway. Together, these results suggest the microRNAs-449/FASN axis as a potential therapeutic target in combination with anti-HER2 agents to overcome trastuzumab resistance and to improve treatment response in HER2-positive breast cancer patients.Keywords
Funding Information
- Asociación Española Contra el Cáncer (PRDVA19016LAME)
- Conselleria d’Educació, Investigació, Cultura i Esport, Generalitat Valenciana (ACIF/2019/119)
- European Union-Next Generation EU (Margarita Salas postdoctoral grant)
- Spanish Government and cofinanced by FEDER Funds (PI21/00002, PI21/00142, PI21/01351)
- Spanish Government CIBERONC (CB16/12/00241, CB16/12/00481)
- Sociedad Española de Oncología Médica (Río Hortega-SEOM)
This publication has 41 references indexed in Scilit:
- miR‐449a: A Promising Biomarker and Therapeutic Target in Cancer and Other DiseasesCell Biochemistry and Biophysics, 2024
- Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancerCellular Oncology, 2023
- MiRNome analysis identifying miR‐205 and miR‐449a as biomarkers of disease progression in intestinal‐type sinonasal adenocarcinomaHead & Neck, 2021
- MicroRNAs as a clue to overcome breast cancer treatment resistanceCancer and Metastasis Reviews, 2021
- MicroRNA-449b-5p suppresses the growth and invasion of breast cancer cells via inhibiting CREPT-mediated Wnt/β-catenin signalingChemico-Biological Interactions, 2019
- Interplay between miRNAs and human diseasesJournal of Cellular Physiology, 2017
- MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cellsTumor Biology, 2014
- Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysisThe Breast, 2011
- Biological functions of microRNAs: a reviewJournal of Physiology and Biochemistry, 2010
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009